Antimicrobial resistance (AMR), rapidly rising worldwide, is now a leading cause of death. Globally, 1.27 million people died as a direct result of AMR in 2019; another 5 million deaths were associated with it. Every year, 48,000 Americans die from antibiotic-resistant infections. In 2023, US public health officials sounded the alarm on an emerging fungus spreading rapidly in health-care facilities, an increase in drug-resistant shigellosis, and the threat of a drug-resistant strain of gonorrhea. The UN plans a high-level meeting in 2024 to address the global menace of AMR. But while conversations around AMR focus on possible solutions, such as the need for new antibiotics, the human cost, already high, continues to rise. The experts on this panel will discuss the danger for patients and the toll already taken, and will look toward building support for life-saving solutions.   

Opening Remarks

Brian Carandang

Associate Director, Business and Program Development, Milken Institute

Moderator

Lynn Goldman

Dean, Milken Institute School of Public Health, George Washington University

Speakers

Gunnar Esiason

Head of Patient Engagement, RA Ventures

Thomas Heymann

President and CEO, Sepsis Alliance

Christine Ann Miller

President and CEO, Melinta Therapeutics

Susan Monarez

Deputy Director, Advanced Research Projects Agency for Health (ARPA-H)